Monoclonal Antibodies for Treatment of COVID

Mar 13, 2022

Monoclonal Antibodies is a treatment offered to people with mild to moderate disease who are most at risk for progression to severe disease. It consists of a 4 hour intravenous infusion, and is usually given in a hospitals.

Currently there are several products available;  Bamlanivimab, Casirivimab (Regeneron), and Sotovovimab (Galaxo product). Only the latter product appears to be effective with Omicron.

Those individual diagnosed with COVID, at risk for severe disease based on vaccination status, age and/or underlying conditions should check with their doctors and local hospitals immediately upon laboratory diagnosis regarding availability and criteria for receiving Monoclonal Antibodies as well as currently available oral antiviral medication. These treatments are effective in reducing the severity of the illness and risk of hospitalization and death and are important measures to control the morbidity and mortality from the virus.